5/28/2020 9:00:56 PM
Immutep Gets US$2.4 Mln R&D Tax Incentive From French Government
4/28/2020 8:07:38 AM
Immutep Announces Further Positive Interim Data From Phase II TACTI-002 Study
3/9/2020 8:11:37 AM
Immutep Gets Second IND Approval For Efti From US FDA
10/10/2019 8:06:50 AM
Immutep Secures A$2.5 Mln R&D Tax Incentive From French Government
9/17/2019 8:09:20 AM
Immutep Secures Japanese Patent Grant For LAG525 Antibody
6/21/2019 8:09:44 AM
Immutep Secures Australian Patent For Eftilagimod Alpha In Chemo-Immunotherapy
9/27/2018 4:42:00 AM
Immutep Enters Agreement With Merck/Pfizer To Investigate Combination Of APC Activator Efti With Avelumab
9/24/2018 8:15:06 AM
Immutep Enters Into Clinical Trial Collaboration And Supply Agreement With Merck KGaA And Pfizer
8/21/2018 4:48:53 AM
Immutep Receives A$1.9 Mln Research And Development Related Tax Rebate From French Government
7/30/2018 10:32:04 PM
Immutep’s LAG-3 Immunostimulant Product Candidate, Efti, Receives IND Approval From U.S. FDA
7/2/2018 8:04:52 AM
Immutep Submits IND Application With FDA For Eftilagimod Alpha
4/12/2018 10:38:22 PM
Immutep Completes A$6.31 Mln Share Purchase Plan; Raises Total Of A$13.16 Mln